MEDICACIÓN IMNUNOLÓGICA PREVENTIVA
NAC 1500 mg diarios
Ivermectina 1 gota por Kg de peso cada 15 dias ( 6mg en 15 ml)
(0.2 mg x kilo de peso, una dosis hoy, repetir al dia siguiente, y luego una dosis semanal)
Quercetina 500 mg (Tripe polifenol 3 capsulas 2 x dia)
Citrato de Zinc 40 mg diarios
Vitamina C 1000 mg diarios
Vitamina D3 7,000 iu diarios (aumentar en caso de resfrio)
PREVENCION COVID
BLOQUEADORES DE RECEPTORES ACE2
TRIPLE POLIFENOL (Quercetina, Cúrcuma, Resveratrol) (Gennadi 2020) ( Fatemeh 2020)
Dosis: 3 cap 2 veces al día con estomago vacio
Extracto de Te verde (Jena et al 2020)
Dosis: 1 capsulas 3 x día con alimentos
Emodina: Sábila (Tin Yun 2007)
ANTIVIRAL PARA LIMPIAR LAS VIA RESPIRATORIAS Propóleos (Bachevski 2020) ( Hiroshi 2020)
Aceite de Copaiba (Barrio et Vela 2020)
Aceite de copaiba agua 9 gotas junto con Propóleos 15 gotas ( en un vaso de agua)
2 a 3 veces al día.
NAC N-acetil cysteina 600 mg (Zhongcheng 2020)
Herbiotic (Tabletas de regaliz y propóleos para Chupar) 3 a 5 x dia. (Harald 2020)
PARA REDUCIR ESTRÉS, Insomnio y ANTI COVID:
Ashwaganda. (extractos de Withanone) (Vipul 2020) ( Acharya 2020)
GAnoderma lucidum (Beta glucanos) ( Murphy 2020)
PROTOCOLO TRATAMIENTO PACIENTE CON COVID
LIPOCUR 1 CUCHARADA 3 VECES AL DÍA ( Fatemeh 2020)
TRIPLE POLIFENOL 3CAP 3 VECES POR DÍA (Gennadi 2020) ( Fatemeh 2020)
Lian Qiao Qin Wen 3 CAP 4 VECES AL DÍA POR 10 A 15 DÍAS (Ke Hu 2020)
Zinc 50 mg
Vitamina D3 10,000 iu diarios (aumentar en caso de resfrio)
NAC (ver dosis abajo)
PARA FORTALECER EL SISTEMA INMUNOLOGICO
Liang Qiao Qing Wen (Ke Hu 2020)
Dosis preventiva: 3 cap 02 veces al día solo 03 cajas personas sanas
3 capsulas 3 x día 5 cajas, personas con comorbilidades
Dos Charla sobre Micronutrientes y Covid:
1 https://avantari.com/videos/
2 https://www.bitchute.com/video/EjrTb9LW8AKz/
Referencias :
Acharya Balkrishna, SUBARNA POKHREL, Jagdeep Singh, Anurag Varshney Withanone from
Withania somnifera May Inhibit Novel Coronavirus (COVID-19) Entry by Disrupting
Interactions between Viral S-Protein Receptor Binding Domain and Host ACE2 Receptor.
Research Square 2020.
Atala B. Jena, Namrata Kanungo, Vinayak Nayak, G.B.N. Chainy, Jagneshwar Dandapat. Catechin
and Curcumin interact with corona (2019-nCoV/SARS-CoV2) viral S protein and ACE2 of
human cell membrane: insights from Computational study and implication for intervention.
Department of Biotechnology, Utkal University. Nature research. 2020.
Bachevski, Dimitri, Katerina Damevska 1, Viktor Simeonovski 1, Maja Dimova. Back to the basics:
Propolis and COVID-19. Dermatol Ther. 2020 Jun 7;e13780.
Barrio Healey, Sacha, José M. Vela Ruiz, Stefany Alfaro Amez Copaiba oil, a therapeutic
proposal for Sars- CoV-2. Medicina naturista, ISSN 1576-3080, Vol. 14, Nº 2, 2020, págs. 126-
128
Fatemeh Zahedipour,1 Seyede Atefe Hosseini,1 Thozhukat Sathyapalan,2 Muhammed Majeed,3
Tannaz Jamialahmadi,4,5 Khalid Al-Rasadi,6 Maciej Banach,7,8 Amirhossein Sahebkar9,
Potential effects of curcumin in the treatment of COVID-19 infection. Biotechnology Research
Center, Pharmaceutical Technology Institute, 2020
Gennadi V. Glinsky Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin
D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation
of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in
Human Cells. Institute of Engineering in Medicine, University of California, San Diego, 9500
Gilman Dr. MC 0435, La Jolla, CA 92093-0435, USA;
Harald Murck. Symptomatic Protective Action of Glycyrrhizin (Licorice)
in COVID-19 Infection? Department of Psychiatry and Psychotherapy, Philipps-
University Marburg, Marburg, Germany. 2Murck-Neuroscience LLC, Westfield, NJ, United
States. 2020
Hiroshi Maruta 1, Hong He 2. PAK1-blockers: Potential Therapeutics against COVID-19. Med
Drug Discover. Apr 2020
Ke Hu,c,1 Wei-jie Guan,b,1 Ying Bi,d,1 Wei Zhang,e,1 Lanjuan Li,f Boli Zhang,g Qingquan Liu,h Yuanlin
Song,i Xingwang Li,j Zhongping Duan,k Qingshan Zheng,l Zifeng Yang,b Jingyi Liang,b Mingfeng
Han,m Lianguo Ruan,n Chaomin Wu,i Yunting Zhang,c Zhen-hua Jia,a,⁎ and Nan-shan Zhong. Efficacy and
safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease
2019: A multicenter, prospective, randomized controlled trial. Phytomedicine. 2020 May 16 : 153242.
Murphy, Emma J , Claire Masterson 2, Emanuele Rezoagli 3, Daniel O'Toole 2, Ian Major 4, Gary D
Stack 5, Mark Lynch 5, John G Laffey 6, Neil J Rowan 7β-Glucan extracts from the same edible
shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and
pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19)
immunotherapies. j.scitotenv.2020.
Siti Khaerunnisa , Hendra Kurniawan, Rizki Awaluddin, Suhartati Suhartati, Soetjipto
Soetjipto. Potential Inhibitor of COVID-19 Main Protease (Mpro) from Several Medicinal Plant
Compounds by Molecular Docking Study
Tin-YunHoaShih-LuWubJaw-ChyunChencChia-ChengLidChien-YunHsiang. Emodin blocks the SARS
coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Research,
Volume 74, Issue 2, May 2007, Pages 92-101
Vipul Kumar,a Jaspreet Kaur Dhanjal,b Sunil C. Kaul,b Renu Wadhwa,b and Durai Sundara
Withanone and caffeic acid phenethyl ester are predicted to interact with main protease
(Mpro) of SARS-CoV-2 and inhibit its activity. J Biomol Struct Dyn. 2020 Jun.
Zhongcheng Shi1,2 and Carlos A Puyo. N-Acetylcysteine to Combat COVID-19: An Evidence
Review. 2020
www.avantari.com
Tienda Virrey Toledo 410 San Isidro +51 933 566 407
Centro Comercial el PoLo II. SURCO. +51 955 347 280
Envios provincias +51 946 016 360
Protocolo Zelenko[1]
Plan de tratamiento para pacientes con síntomas de Covid-19
Manejo pre hospitalario
Dr. Vladimir Zelenko
Pagina web: Vladimirzelenkomd.com
Principios fundamentales
Tratar a los pacientes sobre la base de la sospecha clínica tan pronto como sea
posible, preferiblemente dentro de los primeros 5 días de síntomas. Realice una prueba
de PCR, pero no suspenda el tratamiento a la espera de los resultados.
Riesgo Estratificado de Pacientes
Paciente de bajo riesgo: menor de 45 años, sin comorbilidades y clínicamente estable
Paciente de alto riesgo: mayor de 45, o menor de 45 con comorbilidades o clínicamente
inestable.
Opciones de tratamiento
Pacientes de bajo riesgo, opciones de venta libre (sin prescripción médica):
1. Zinc elemental 50mg 1 vez al día por 7 días[2]
2. Quercetina 500mg 2 veces al día por 7 días [3] o
Galato de Epigalocatequina (EGCG) 400mg 1 vez al día por 7 días [4]
3. Vitamina C 1000mg 1 vez al día por 7 días
4. Vitamina D3 5000 iu 1 vez al día por 7 días
Pacientes de Alto Riesgo
1. Zinc elemental 50mg 1 vez al día por 7 días
2. Hidroxicloroquina (HCQ) 200mg 2 veces al día por 7 días
Si HCQ no está disponible, utilice Quercetina 500mg 3 veces al día por 7 días o
Galato de Epigalocatequina (EGCG) 400mg 2 veces al día por 7 días.
3. Azitromicina 500mg 1 vez al día por 5 días o
Doxiciclina 100mg 2 vez al día por 7 días
4. Vitamina C 1000mg 1 vez al día por 7 días
5. Vitamina D3 50000iu 1 vez al día por 1 o 2 días
Otras opciones de tratamiento
1. Ivermectina 6mg 2 veces al día por 1 o 2 días [5]
2. Budesonida 1mg/2cc solución vía nebulizador 2 veces al día por 7 días [6]
3. Dexametasona 8mg 1 vez al día por 7 días[7]
4. Anticoagulantes (por ejemplo: Lovenox)[8]
5. Tratamiento ambulatorio con anticuerpos monoclonales como cóctel REGN-COV2 o
Bamlanivimab
6. Terapia en el hogar de infusión intravenosa con fluidos y oxigeno
TRATE DE MANTENER A LOS PACIENTES
FUERA DEL HOSPITAL
[1]
https://www.preprints.org/manuscript/202007.0025/v1
[2]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365891/
[3]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318306/
[4]
https://pubs.acs.org/doi/10.1021/jf5014633
[5]
https://www.sciencedirect.com/science/article/pii/S0166354220302011
[6]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392554/
[7]
https://www.nejm.org/doi/full/10.1056/NEJMoa2021436
[8]
https://www.onlinejacc.org/content/76/1/122?_ga=2.33698596.423106752.1597365568-
1776897998.1597365568
N-Acetylcysteine to Combat COVID-19: An Evidence Review
Zhongcheng Shi1,2 and Carlos A Puyo3
Abstract
The Strategy of NAC Administration
To protect those who have not contracted SARS-Cov-2, oral NAC (600 mg, bid) could be an
effective and economical measurement to modulate their immune systems against potential
infection. Once onset symptoms appear, such as fever or dry cough, oral NAC (1200 mg, bid)
could be taken to alleviate symptoms and accelerate recovery from virus infection.
For relatively severe patients without airway obstructions, an inhalable formula of NAC can be
used with a nebulizer. Patients with allergies or asthma should take antihistamine before or
during NAC inhalation, to prevent adverse reactions. Self-treatment with oral or inhalable NAC
could help many SARS-Cov-2 infected patients safely recover at home.
Once patients develop clinically confirmed pneumonia or dyspnea, in addition to regular therapy,
such as Remdesivir,53 IV NAC should be given intermittently or continuously. This could then
prevent development of ARDS, which often entails invasive ventilation and intensive care unit
support. For example, NAC can be infused at a dose of 100 mg/kg for at least 3 days, which
equals to about 1/3 of the total dose during a 3-bag regime. There is no difference between
intermittent and continuous infusion of NAC regarding patient outcomes.54
When a patient develops ARDS, along with regular antiviral therapy, 150 mg/kg at the first day,
followed by a dose of 100 mg/kg/day for at least 3 days, should be administrated to avoid
irreversibly fatal multiple organ failure (MOF). Once MOF or critical sepsis occurs, patients
likely will not benefit from any NAC administration.55 A brief overview of a NAC therapeutic
strategy to combat COVID-19 has been summarized in Figure 4.
Conclusions
N-acetylcysteine (NAC) is inexpensive, has very low toxicity, has been FDA approved for many
years, and has the potential to improve therapeutic strategies for COVID-19. NAC administered
intravenously, orally, or inhaled, may suppress SARS-CoV-2 replication and may improve
outcomes if used timely. Potential therapeutic benefits of NAC include, extracellularly
scavenging ROS radicals, replenishing intracellular GSH, suppression of cytokine storm, and T
cell protection, thus mitigating inflammation and tissue injury. NAC administration in
combination with other antiviral agents may dramatically reduce hospital admission rate,
mechanical ventilation and mortality.
